More than 9 out of 10 Alzheimer’s cases could be driven by specific variations in a single gene and the protein it produces, a new study reveals, suggesting that treatments targeting this well-known gene could prevent the disease from developing in the majority of instances.
The gene in question, APOE, has long been associated with Alzheimer’s risk. What’s new here is the way the different variations of the gene have been analysed and mapped against the chances of developing Alzheimer’s. It turns out that the APOE combination we’re born with could be even more important than previously realized.
Researchers led by a team from University College London (UCL) took a fresh look at the three main variations of the APOE gene: ε2 (linked to a protective effect against cognitive decline), ε3 (historically considered the normal or neutral version), and ε4 (already known to significantly increase Alzheimer’s risk).
Nearly all Alzheimer’s, and half of dementia, is driven by APOE.
— Dr. Rhonda Patrick (@foundmyfitness) January 9, 2026
A new, large-scale analysis reports that up to 93% of Alzheimer’s cases and 85% of brain amyloid burden are attributable to having an APOE ε3/ε4 genotype, and the combined contribution of ε3 and ε4 to all-cause… pic.twitter.com/lbP5NZJ4q7
Leave a Reply
You must be logged in to post a comment.